Retinal Disease Clinical Trials

39 recruitingLast updated: June 18, 2026

There are 39 actively recruiting retinal disease clinical trials across 20 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Early Phase 1, Phase 4. Top locations include Durham, North Carolina, United States, Ann Arbor, Michigan, United States, Dallas, Texas, United States. Updated daily from ClinicalTrials.gov.


Retinal Disease Trials at a Glance

39 actively recruiting trials for retinal disease are listed on ClinicalTrialsFinder across 6 cities in 20 countries. The largest study group is Not Applicable with 11 trials, with the heaviest enrollment activity in Durham, Ann Arbor, and Dallas. Lead sponsors running retinal disease studies include Duke University, National Eye Institute (NEI), and Laboratoires Thea.

Browse retinal disease trials by phase

Treatments under study

About Retinal Disease Clinical Trials

Looking for clinical trials for Retinal Disease? There are currently 26 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Retinal Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Retinal Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 39 trials

Recruiting

Cell Collection to Study Eye Diseases

Retinal DegenerationRetinitis PigmentosaRetinal Disease+1 more
National Eye Institute (NEI)930 enrolled1 locationNCT01432847
Recruiting

Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene

Retinal DiseaseGenotype
National Eye Institute (NEI)320 enrolled1 locationNCT01145196
Recruiting

National Eye Institute Biorepository for Retinal Diseases

Age-Related Macular DegenerationDiabetic RetinopathyRetinal Disease+2 more
National Eye Institute (NEI)650 enrolled1 locationNCT01496625
Recruiting
Phase 3

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

Sensation DisordersLeber Congenital AmaurosisRetinal Disease+7 more
Laboratoires Thea32 enrolled16 locationsNCT06891443
Recruiting

Establishment of a Multimodal Standard Database for Inflammation-related Ophthalmopathy

Inflammatory DiseaseRetinal DiseaseOcular Surface Disease+1 more
Dan Chen3,000 enrolled1 locationNCT07628946
Recruiting

Inherited Retinal Degenerative Disease Registry

Retinitis PigmentosaBatten DiseaseLeber Congenital Amaurosis+25 more
Foundation Fighting Blindness20,000 enrolled1 locationNCT02435940
Recruiting
Not Applicable

COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Inherited Retinal Disease

Retinal Disease
University of Wisconsin, Madison50 enrolled1 locationNCT06380075
Recruiting
Not Applicable

Defining Retinal Structures Using Hyperspectral Retinal Imaging

Retinal diseasesHealthy VolunteersAge-Related Macular Degeneration+2 more
Center for Eye Research Australia1,000 enrolled1 locationNCT07555574
Recruiting
Phase 1Phase 2

A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

Retinitis pigmentosa (RP)Retinal DegenerationPrimary Photoreceptor Disease+6 more
BlueRock Therapeutics54 enrolled4 locationsNCT06789445
Recruiting
Phase 2

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

deaf-blindRetinitis pigmentosa (RP)Retinal Disease+4 more
Laboratoires Thea81 enrolled27 locationsNCT06627179
Recruiting
Not Applicable

Advancing Pediatric Retinal Imaging With Auto-aligned OCT

Retinal DiseaseGlaucomaOptic Nerve Diseases+1 more
Duke University50 enrolled1 locationNCT06841575
Recruiting
Not Applicable

Optimizing Low Vision Rehabilitation in Emotionally Distressed Patients With Inherited Retinal Diseases

Inherited Retinal Diseases
University of Michigan180 enrolled1 locationNCT06651736
Recruiting

Longitudinal Observational Study of Diabetic Retinopathy Progression in Type 2 Diabetes Patients

Diabetes Mellitus, Type 2Diabetic RetinopathyDiabetic Complication+1 more
Association for Innovation and Biomedical Research on Light and Image100 enrolled1 locationNCT07458516
Recruiting

Data Gathering for A10900

HealthyRetinal DiseaseGlaucoma+1 more
Optos, PLC180 enrolled4 locationsNCT07149740
Recruiting
Not Applicable

4D Duke Microscope Integrated Optical Coherence Tomography in a Zeiss Artevo 800

Retinal diseasesOcular DiseasesCorneal Diseases
Duke University5 enrolled1 locationNCT07024719
Recruiting
Not Applicable

The Genetics Navigator: Evaluating a Digital Platform for Genomics Health Services

Cardiac conditionsCancerConnective Tissue Diseases+4 more
Unity Health Toronto170 enrolled3 locationsNCT06455384
Recruiting
Phase 2

SGLT2 Inhibitors in Geographic Atrophy

Geographic AtrophyRetinal diseasesRetinal Degeneration+2 more
Washington University School of Medicine70 enrolled1 locationNCT07174687
Recruiting
Not Applicable

CHOPXE - Analysis of Choriocapillaris Flow Deficits in Patients With Pseudoxanthoma Elasticum

Retinal DiseaseTomography Optical CoherencePseudoxanthoma Elasticum
University Hospital, Angers60 enrolled1 locationNCT07006649
Recruiting
Phase 1Phase 2

A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001

Retinal DegenerationRetinal DiseaseRetinal Dystrophies+2 more
PYC Therapeutics16 enrolled6 locationsNCT06852963
Recruiting
Phase 1Phase 2

A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)

Retinitis PigmentosaChoroideremiaNon-Syndromic Rod-Dominant Inherited Retinal Diseases
Kiora Pharmaceuticals, Inc.48 enrolled3 locationsNCT05282953